-
New research finds the shingles vaccine can also prevent dementia and cardiovascular disease
02 Mar 2026 20:03 GMT
… you that I had a drug that would reduce your risk … actually seem to have that drug. So the evidence first accumulated … another vaccine that has that same strong immune stimulant, that same adjuvant … , and that's the vaccine that is against …
-
KEYTRUDA® (pembrolizumab) Plus WELIREG® (belzutifan) Given as Adjuvant Therapy Reduced the Risk of Disease Recurrence or Death by 28% Compared to KEYTRUDA Monotherapy in Certain Patients With Earlier-Stage Renal Cell Carcinoma (RCC)
28 Feb 2026 17:07 GMT
… across multiple settings, including adjuvant and advanced disease.
… Stevens-Johnson syndrome, drug rash with eosinophilia and … of important medicines and vaccines. We aspire to … : SCIENCE BIOTECHNOLOGY RESEARCH PHARMACEUTICAL ONCOLOGY GENERAL HEALTH HEALTH …
-
Contraceptive vaccine reduces fertility in animals to address wildlife overpopulation
27 Feb 2026 21:49 GMT
… of existing contraceptive vaccines.”
HogenEsch disclosed the contraceptive vaccine to the … chain interruptions.
HogenEsch’s contraceptive vaccine addresses these limitations.
“It … and an effective and safe adjuvant.”
Validation and next development steps …
-
RSV Vaccine Demonstrates Cardioprotective Effects, Reduces MACE and Hospitalizations, With Deepak Bhatt, MD, MPH
27 Feb 2026 01:58 GMT
… (RSV) Vaccine, Adjuvanted (Arexvy), has highlighted the vaccine’s efficacy … al. Effectiveness of adjuvanted RSVPreF3 vaccine in preventing major adverse … ;publications/effectiveness-adjuvanted-rsvpref3-vaccine-preventing-major-adverse-cardiovascular
-
COVID-19 Vaccine Maker Novavax Swings To Profit As Sales Climb
26 Feb 2026 19:28 GMT
Novavax Inc. (NASDAQ:NVAX) shares are up on Thursday following the company’s announcement of its fourth-quarter and full-year 2025 financial results.
Earnings
Novavax reported fourth-quarter earnings of 11 cents, a shift from a loss of 51 cents a year ago. …
-
Novavax raises revenue forecast on boost from vaccine deals; shares soar
26 Feb 2026 16:45 GMT
… posed a risk for vaccine companies.
The company’s … poses some significant uncertainties for vaccine companies,” Jacobs said, but … U.S. Food and Drug Administration initially refused to review … M adjuvant, which improves the body’s response to vaccines, to …
-
SK Bioscience Secures EU Influenza Vaccine Development Project
26 Feb 2026 14:03 GMT
… foothold for domestically developed influenza vaccine technology to enter the demanding … , and its pandemic (avian influenza) vaccine currently under development, while conducting … such as high-dose and adjuvanted vaccines due to diminished immune responses …
-
SK bioscience, IDT Biologika and Vaxxas Selected for Next-Generation Influenza Vaccine development Financed by the European Union
26 Feb 2026 13:52 GMT
… in Europe, including responsibility for drug substance production.
SK bioscience, … such as high-dose and adjuvanted vaccines, making differentiated formulations and technologies … global vaccine market.
About IDT Biologika
With passion we bring pharmaceutical …
-
Novavax raises 2026 adjusted revenue outlook on strength in vaccine deals
26 Feb 2026 13:39 GMT
… it expects milestone payments from vaccine supply and licensing deals … U.S. Food and Drug Administration initially refused to review … a COVID-flu combination vaccine that uses its Nuvaxovid … M adjuvant, which improves the body’s response to vaccines, to …
-
Myriad Commercially Launches Precise MRD with Select Community Oncologists
02 Mar 2026 21:05 GMT
SALT LAKE CITY, March 02, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announces the launch of the Precise MRD™ (molecular residual disease) test with a select number …
About
© 1995-2026